| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/20/2006 | WO2006044687A3 Kinase inhibitors |
| 07/20/2006 | WO2006036291A3 Antibodies directed against amyloid-beta peptide and methods using same |
| 07/20/2006 | WO2006026532A3 Methods of treatment of amyloidosis using substituted ethanolcyclicamine aspartyl protease inhibitors |
| 07/20/2006 | WO2006024018A3 Compositions for treating nociceptive pain |
| 07/20/2006 | WO2005120487A3 Preparation for the prevention and treatment of stress conditions as well as functional and organic disorders of the nervous system and metabolic disorders |
| 07/20/2006 | WO2005058363A3 Pharmaceutical composition of a sodium channel blocker and a selective serotonin uptake inhibitor |
| 07/20/2006 | WO2005042472A3 Hydroxypropyl amides for the treatment of alzheimer’s disease |
| 07/20/2006 | US20060161004 Quinoline derivatives for therapy and prophylaxis of chronic obstructive pulmonary disease (COPD), asthma, airway hyper-reactivity, cough, inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis |
| 07/20/2006 | US20060160881 Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan |
| 07/20/2006 | US20060160878 For therapy of central nervous system disorders related to or affected by the 5-HT6 receptor |
| 07/20/2006 | US20060160877 2-Heteroaryl carboxamides |
| 07/20/2006 | US20060160848 Method of controlling damage mediated by alpha, beta-unsaturated aldehydes |
| 07/20/2006 | US20060160846 Quinoline derivatives |
| 07/20/2006 | US20060160842 in brain; (2,5-difluorodifluorophenyl)-N-methyl-N-((1-propylbenzimidazol-2-yl)methyl)carboxamide; anxiolitic and antidepressant; finding and altering the signal-transducing activity of gamma aminobutyric acid (GABA) receptors; detectably-labeled antagonist/agonist of GABAR |
| 07/20/2006 | US20060160835 Methods and compositions for treatment of central nervous system disorders |
| 07/20/2006 | US20060160829 Thienopyrimidine compounds and use thereof |
| 07/20/2006 | US20060160824 Indole derivatives as serotonin reuptake inhibitors |
| 07/20/2006 | US20060160816 Pirazino(AZA) indole derivatives |
| 07/20/2006 | US20060160808 New carboxylic acid derivatives, their preparation and their use |
| 07/20/2006 | US20060160797 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 07/20/2006 | US20060160768 Novel polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative |
| 07/20/2006 | US20060160726 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors |
| 07/20/2006 | US20060160194 Process for the production of biodegradeable, functionalised polymer particles, and use thereof as pharmaceutical supports |
| 07/20/2006 | US20060160146 Method of screening compound affecting amyloid beta production |
| 07/20/2006 | US20060160145 Assay that makes use of the interaction of early pregnancy factor (EPF) or an EPF-related peptide with a human dorsal root receptor (hDRR) or hDRR related receptor; also useful to determine whether the test compound is an agonist or antagonist of hDRRs |
| 07/20/2006 | US20060160132 Diagnositics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a) |
| 07/20/2006 | US20060160083 Diagnositics and therapeutics for diseases associated with human g-protein couple receptor 14 (gpr14) |
| 07/20/2006 | US20060160079 Methods for the treatment of dementia based on apo e genotype |
| 07/20/2006 | US20060159790 Composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative or an extract of a plant of genus angelicae containing same |
| 07/20/2006 | US20060159768 Quetiapine granules |
| 07/20/2006 | US20060159751 Controlled release pharmaceutical compositions of carbidopa and levodopa |
| 07/20/2006 | US20060159749 Mesalamine inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices |
| 07/20/2006 | US20060159655 Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor |
| 07/20/2006 | US20060159626 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 07/20/2006 | US20060159624 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant; sleep disorders |
| 07/20/2006 | US20060157491 Dispenser with reservoir containing a drug of abuse |
| 07/20/2006 | CA2595159A1 Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| 07/20/2006 | CA2595126A1 Methods and compositions for preventing and treating a disease related to glycan dysregulation |
| 07/20/2006 | CA2594484A1 Cinnamate salts of a beta-2 adrenergic agonist |
| 07/20/2006 | CA2594340A1 Aminophenyl derivatives as selective androgen receptor modulators |
| 07/20/2006 | CA2593515A1 Amino-imidazolones for the inhibition of beta-secretase |
| 07/20/2006 | CA2593439A1 Thiazole-4-carboxamide derivatives as mglur5 antagonists |
| 07/20/2006 | CA2593274A1 Glycine reuptake inhibitors for treating drug and alcohol dependence |
| 07/20/2006 | CA2592723A1 4- (1h-indol-3-yl) -pyrimidin-2-ylamine derivates and their use in therapy |
| 07/20/2006 | CA2592611A1 2-(cyclic aminocarbonyl)indoline derivative and medicinal composition containing the same |
| 07/20/2006 | CA2591487A1 Polymorphs of memantine hydrochloride |
| 07/20/2006 | CA2590664A1 Macrocyclic compounds and compositions useful as bace inhibitors |
| 07/19/2006 | EP1681354A2 Recombinant viruses coding for a glutamate decarboxylase (gad) |
| 07/19/2006 | EP1681063A1 Agent for improving mental disorders |
| 07/19/2006 | EP1681058A2 Pharmacologically active cns compounds |
| 07/19/2006 | EP1681057A1 Use of naloxone for treating eating disorders |
| 07/19/2006 | EP1681051A1 Multi-layer controlled-release tablet comprising an active layer and one or more barrier layers |
| 07/19/2006 | EP1680421A2 Use of tricyclic compounds as glycine transport inhibitors |
| 07/19/2006 | EP1680418A2 Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics |
| 07/19/2006 | EP1680402A1 Derivatives of n-[[phenyl(piperidine-2-yl)methyl]benzamide, preparation method thereof and applications of same in therapeutics |
| 07/19/2006 | EP1680400A2 Derivatives of n-[ phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[ (azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics |
| 07/19/2006 | EP1680145A2 Methods and compositions for the treatment of neurological disease |
| 07/19/2006 | EP1680126A1 Neuroprotection with beta-lactam compounds |
| 07/19/2006 | EP1680113A2 Dopamine-, norepinephrine- and serotonin- transporter- selective heterocyclic compounds and their therapeutic applications |
| 07/19/2006 | EP1680111A2 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| 07/19/2006 | EP1679967A2 Methods of using and compositions comprising selective cytokine inhibitory drus for treatment, modification and management of pain |
| 07/19/2006 | EP1532124B1 Use of nitrile derivatives as medicament. |
| 07/19/2006 | EP1506194B1 SUBSTITUTED RING-FUSED IMIDAZOLE DERIVATES: GABA sb A /sb RECEPTOR LIGANDS |
| 07/19/2006 | EP1444215B1 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| 07/19/2006 | EP1395575B1 4-(penyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 07/19/2006 | EP1379695B1 New polynucleotides and polypeptides of the ifnalpha-21 gene |
| 07/19/2006 | EP1372640B1 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders |
| 07/19/2006 | EP1370556B1 Metalloproteinase inhibitors |
| 07/19/2006 | EP1301507B1 Mannich base prodrugs of 3 - (pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 07/19/2006 | EP1276880B1 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 07/19/2006 | EP1268453B1 Estrogen agonist/antagonist metabolites |
| 07/19/2006 | EP1223930B1 Treatment of dyskinesia |
| 07/19/2006 | EP1164991A4 Gels formed by the interaction of poly(aldehyde) with various substances |
| 07/19/2006 | EP1121109B8 Biphasic tramadol preparation |
| 07/19/2006 | EP1077697B1 Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| 07/19/2006 | EP1056452B1 Indole-3-propionic acids, salts and esters thereof used as medicaments |
| 07/19/2006 | CN1805963A Cannabinoid receptor ligands and uses thereof |
| 07/19/2006 | CN1805957A Azetidine compounds |
| 07/19/2006 | CN1805954A Indole derivatives as serotonin reuptake inhibitors |
| 07/19/2006 | CN1805953A Indole derivatives as serotonin reuptake inhibitors |
| 07/19/2006 | CN1805944A Cyclic hydroxylamine as psychoactive compounds |
| 07/19/2006 | CN1805940A Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 07/19/2006 | CN1805939A Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases |
| 07/19/2006 | CN1805938A Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases |
| 07/19/2006 | CN1805937A N-[(piperazinyl)hetaryl]arylsulfonamide compounds with affinity for the dopamine D3 receptor. |
| 07/19/2006 | CN1805929A Phosphodiesterase 4 inhibitors |
| 07/19/2006 | CN1805769A CNS chloride modulation and uses thereof |
| 07/19/2006 | CN1805747A 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's |
| 07/19/2006 | CN1805746A Treatment for alzheimer's disease and related conditions |
| 07/19/2006 | CN1805743A RAGE antagonists as agents to reverse amyloidosis and diseases associated therewith |
| 07/19/2006 | CN1805685A Treatment of demyelinating conditions |
| 07/19/2006 | CN1804042A Promotion of nerve cell differentiation by human14-3-3 yupsilon protein |
| 07/19/2006 | CN1803842A Antibody for treating or preventing senile dementia, its expression vector and application in drug preparation |
| 07/19/2006 | CN1803837A Neurotrophic growth factor |
| 07/19/2006 | CN1803795A Substituted piperidine compounds for use as h3 histamine receptor antagonists |
| 07/19/2006 | CN1803784A 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives |
| 07/19/2006 | CN1803193A Use of stroma stem cell derived from bone marrow in preparing formulation for treating hypoxic ischemic cerebral palsy |
| 07/19/2006 | CN1803180A Medicine composition and its preparation method and quality control method |
| 07/19/2006 | CN1803128A Oral disintegrating tablet containing tramadol hydrochloride and acetaminopher, and its preparation method |
| 07/19/2006 | CN1803126A Compound nicholin formulation and its preparation method and uses |